STOCK TITAN

[SCHEDULE 13G/A] RxSight, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Bank of America Corporation reports beneficial ownership of 172,091 shares of RxSight, Inc. common stock, representing 0.4% of the class. The filing shows 0 shares with sole voting or dispositive power, 151,216 shares with shared voting power and 172,091 with shared dispositive power, reflecting holdings across Bank of America and several wholly owned subsidiaries. The statement affirms the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Ownership is below the 5% threshold that typically signals a controlling stake.

La Bank of America Corporation dichiara la titolarità beneficiaria di 172.091 azioni ordinarie di RxSight, Inc., pari a 0,4% della classe. Il deposito indica 0 azioni con potere di voto o di disposizione esclusivo, 151.216 azioni con potere di voto condiviso e 172.091 con potere di disposizione condiviso, riflettendo partecipazioni distribuite tra Bank of America e varie controllate interamente possedute. La dichiarazione conferma che le azioni sono detenute nell'ordinario svolgimento dell'attività e non sono state acquistate per modificare o influenzare il controllo dell'emittente. La partecipazione è al di sotto della soglia del 5% che normalmente segnala una posizione di controllo.

Bank of America Corporation declara la titularidad beneficiaria de 172.091 acciones ordinarias de RxSight, Inc., lo que representa el 0,4% de la clase. El documento muestra 0 acciones con poder de voto o de disposición exclusivo, 151.216 acciones con poder de voto compartido y 172.091 con poder de disposición compartido, reflejando participaciones repartidas entre Bank of America y varias filiales de propiedad total. La declaración afirma que las acciones se mantienen en el curso ordinario del negocio y no se adquirieron para cambiar o influir en el control del emisor. La participación está por debajo del umbral del 5% que normalmente indica una posición de control.

Bank of America Corporation은 RxSight, Inc. 보통주 172,091주를 실질적 소유자로 보고했으며, 이는 해당 클래스의 0.4%에 해당합니다. 제출 서류에는 단독 의결권 또는 처분권을 가진 주식이 0주, 공동 의결권을 가진 주식이 151,216주, 공동 처분권을 가진 주식이 172,091주로 기재되어 있으며, 이는 Bank of America와 여러 전액 출자 자회사의 보유를 반영합니다. 성명서는 이 주식들이 통상적인 영업 과정에서 보유되고 있으며 발행인의 지배권을 변경하거나 영향을 미치기 위해 취득된 것이 아님을 확인합니다. 보유 비율은 일반적으로 지배 지분을 의미하는 5% 기준을 밑돌고 있습니다.

Bank of America Corporation déclare détenir en qualité de bénéficiaire 172 091 actions ordinaires de RxSight, Inc., représentant 0,4% de la catégorie. Le dépôt indique 0 action avec pouvoir de vote ou de disposition exclusif, 151 216 actions avec pouvoir de vote partagé et 172 091 avec pouvoir de disposition partagé, reflétant des avoirs répartis entre Bank of America et plusieurs filiales détenues en totalité. La déclaration précise que les actions sont détenues dans le cours normal de l'activité et n'ont pas été acquises pour modifier ou influencer le contrôle de l'émetteur. La participation est inférieure au seuil de 5% qui signale généralement une position de contrôle.

Die Bank of America Corporation meldet wirtschaftliches Eigentum an 172.091 Aktien der Stammaktien von RxSight, Inc., was 0,4% der Klasse entspricht. Die Meldung weist 0 Aktien mit alleinigem Stimm- oder Verfügungsrecht, 151.216 Aktien mit gemeinsamem Stimmrecht und 172.091 mit gemeinsamem Verfügungsrecht aus und spiegelt Beteiligungen der Bank of America sowie mehrerer vollständig im Eigentum stehender Tochtergesellschaften wider. Die Erklärung bestätigt, dass die Aktien im normalen Geschäftsverlauf gehalten werden und nicht erworben wurden, um die Kontrolle über den Emittenten zu ändern oder zu beeinflussen. Die Beteiligung liegt unter der 5%-Schwelle, die üblicherweise auf eine beherrschende Stellung hinweist.

Positive
  • Transparent disclosure of beneficial ownership: 172,091 shares representing 0.4% of RxSight common stock
  • Certification of ordinary‑course holdings, stating the position was not acquired to influence control
Negative
  • None.

Insights

TL;DR: Non‑material institutional stake; routine disclosure with shared custody characteristics.

Bank of America’s reported 172,091‑share position (0.4%) is immaterial to RxSight’s capital structure and unlikely to affect operations or strategic direction. The split between shared voting power (151,216) and shared dispositive power (172,091) suggests holdings managed across multiple BofA entities, consistent with brokerage, custody or client‑related positions rather than an active control intent. The certification that the position is held in the ordinary course reinforces a passive posture.

TL;DR: Schedule 13G/A indicates passive ownership across bank and broker subsidiaries, not a control claim.

The filing names Bank of America Corporation and identifies specific subsidiaries (broker‑dealers, a bank and a non‑U.S. institution) as holders. The explicit statement that the securities were not acquired to change or influence control and the classification under Schedule 13G/A are consistent with passive investor status. From a governance perspective, this disclosure is routine and does not signal governance change or activist intent.

La Bank of America Corporation dichiara la titolarità beneficiaria di 172.091 azioni ordinarie di RxSight, Inc., pari a 0,4% della classe. Il deposito indica 0 azioni con potere di voto o di disposizione esclusivo, 151.216 azioni con potere di voto condiviso e 172.091 con potere di disposizione condiviso, riflettendo partecipazioni distribuite tra Bank of America e varie controllate interamente possedute. La dichiarazione conferma che le azioni sono detenute nell'ordinario svolgimento dell'attività e non sono state acquistate per modificare o influenzare il controllo dell'emittente. La partecipazione è al di sotto della soglia del 5% che normalmente segnala una posizione di controllo.

Bank of America Corporation declara la titularidad beneficiaria de 172.091 acciones ordinarias de RxSight, Inc., lo que representa el 0,4% de la clase. El documento muestra 0 acciones con poder de voto o de disposición exclusivo, 151.216 acciones con poder de voto compartido y 172.091 con poder de disposición compartido, reflejando participaciones repartidas entre Bank of America y varias filiales de propiedad total. La declaración afirma que las acciones se mantienen en el curso ordinario del negocio y no se adquirieron para cambiar o influir en el control del emisor. La participación está por debajo del umbral del 5% que normalmente indica una posición de control.

Bank of America Corporation은 RxSight, Inc. 보통주 172,091주를 실질적 소유자로 보고했으며, 이는 해당 클래스의 0.4%에 해당합니다. 제출 서류에는 단독 의결권 또는 처분권을 가진 주식이 0주, 공동 의결권을 가진 주식이 151,216주, 공동 처분권을 가진 주식이 172,091주로 기재되어 있으며, 이는 Bank of America와 여러 전액 출자 자회사의 보유를 반영합니다. 성명서는 이 주식들이 통상적인 영업 과정에서 보유되고 있으며 발행인의 지배권을 변경하거나 영향을 미치기 위해 취득된 것이 아님을 확인합니다. 보유 비율은 일반적으로 지배 지분을 의미하는 5% 기준을 밑돌고 있습니다.

Bank of America Corporation déclare détenir en qualité de bénéficiaire 172 091 actions ordinaires de RxSight, Inc., représentant 0,4% de la catégorie. Le dépôt indique 0 action avec pouvoir de vote ou de disposition exclusif, 151 216 actions avec pouvoir de vote partagé et 172 091 avec pouvoir de disposition partagé, reflétant des avoirs répartis entre Bank of America et plusieurs filiales détenues en totalité. La déclaration précise que les actions sont détenues dans le cours normal de l'activité et n'ont pas été acquises pour modifier ou influencer le contrôle de l'émetteur. La participation est inférieure au seuil de 5% qui signale généralement une position de contrôle.

Die Bank of America Corporation meldet wirtschaftliches Eigentum an 172.091 Aktien der Stammaktien von RxSight, Inc., was 0,4% der Klasse entspricht. Die Meldung weist 0 Aktien mit alleinigem Stimm- oder Verfügungsrecht, 151.216 Aktien mit gemeinsamem Stimmrecht und 172.091 mit gemeinsamem Verfügungsrecht aus und spiegelt Beteiligungen der Bank of America sowie mehrerer vollständig im Eigentum stehender Tochtergesellschaften wider. Die Erklärung bestätigt, dass die Aktien im normalen Geschäftsverlauf gehalten werden und nicht erworben wurden, um die Kontrolle über den Emittenten zu ändern oder zu beeinflussen. Die Beteiligung liegt unter der 5%-Schwelle, die üblicherweise auf eine beherrschende Stellung hinweist.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



BANK OF AMERICA CORP /DE/
Signature:Andres Ortiz
Name/Title:Authorized Signatory
Date:08/12/2025

FAQ

How many RxSight (RXST) shares does Bank of America report owning?

Bank of America reports owning 172,091 shares of RxSight common stock, representing 0.4% of the class.

Does Bank of America have voting control over RxSight (RXST)?

No. The filing shows 0 shares with sole voting power and states the securities are held in the ordinary course of business and not to influence control.

Which Bank of America entities are identified as holders of the RXST position?

The statement is filed on behalf of Bank of America Corporation and wholly owned subsidiaries, including BofA Securities, Inc., Bank of America N.A., Merrill Lynch Pierce Fenner & Smith, Inc., and Merrill Lynch International.

Is this a 5% ownership filing for RxSight (RXST)?

No. The reported ownership is 0.4%, which is below the 5% level that typically indicates a larger, potentially controlling stake.

What type of SEC filing is this and what does it signify?

This is a Schedule 13G/A amendment disclosing beneficial ownership under rules for passive or ordinary‑course holdings rather than active control filings.
Rxsight, Inc.

NASDAQ:RXST

RXST Rankings

RXST Latest News

RXST Latest SEC Filings

RXST Stock Data

300.73M
38.41M
5.52%
98.89%
12.2%
Medical Devices
Ophthalmic Goods
Link
United States
ALISO VIEJO